RCUS
What one share of Arcus Biosciences holds
Pharmaceutical Preparations
We are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs.
Arcus Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.98 |
|---|---|
| Profit | −$3.86 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.99 |
| Cash and investments | $1.18 |
| Debt | $0.80 |
| Book value | $3.65 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$20.80 | $4.74 | −$19.73 | — | — |
| 2017 | $0.77 | −$29.03 | $3.02 | −$16.72 | — | — |
| 2018 | $0.24 | −$1.43 | $0.11 | −$1.35 | — | $5.28 |
| 2019 | $0.34 | −$1.93 | $0.04 | −$1.72 | — | $3.57 |
| 2020 | $1.42 | −$2.24 | $0.05 | $1.97 | — | $7.71 |
| 2021 | $5.18 | $0.72 | $0.35 | −$3.81 | — | $11.89 |
| 2022 | $1.56 | −$3.71 | $0.08 | $6.00 | — | $9.01 |
| 2023 | $1.58 | −$4.15 | $0.32 | −$4.46 | — | $6.12 |
| 2024 | $2.86 | −$3.14 | $0.07 | −$1.95 | — | $5.26 |
| 2025 | $2.30 | −$3.29 | $0.02 | −$4.51 | — | $5.04 |